TirzepatideRanked
Find my match
Price index re-read 2026-10-15 NexLife prices 2026-11-06 Methodology v4.1 Programs priced 28 Corrections open log

Pillar / Money

Tirzepatide Cost Without Insurance

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Direct answer

Without insurance, brand Zepbound costs $299 to $449 a month on Lilly’s self-pay card (last read October 15, 2026; Lilly refused our November 20 re-read), and the FDA-approved pills Foundayo and Wegovy start at $149. Compounded tirzepatide runs $69 to $299 a month across the 33 programs in our November 20, 2026 index (median $149); NexLife charges $129 month to month, or $115 a month on a 12-month plan.

Answer last reviewed:

Start with the manufacturer, not a platform

The single most expensive mistake in self-pay GLP-1 purchasing is buying a brand-name drug through a telehealth platform that resells it near retail. Our dataset contains brand Wegovy at $1,794 a month all-in from one provider and brand Mounjaro at $2,048 from another. NovoCare sells Wegovy direct for $349. Lilly runs no self-pay programme for Mounjaro, but Zepbound is the same molecule at $299 to $449.

That is a four to twelvefold difference for the identical medicine, and it is disclosed pricing rather than fraud. Price any brand drug at LillyDirect or NovoCare before buying it anywhere else.

The self-pay ladder in 2026

$110–$147 — compounded microdose programmes, on twelve-month plans. Below every dose studied in the trials.

$149 — FDA-approved oral orforglipron or oral Wegovy tablets, at starting doses. Reviewed for safety, effectiveness and quality.

$169–$215 — the lower band of standard compounded injectable programmes.

$299–$449 — brand Zepbound direct from LillyDirect, by dose tier.

$278–$399 — the upper band of compounded programmes, which overlaps the brand band.

Where self-pay logic breaks down

The overlap in that ladder is the finding. A compounded programme at $349 costs more than the approved injectable at $299 and more than twice the approved oral. Whatever the argument for compounded medicine is at that price, it is not a cost argument.

The cost argument holds firmly at the bottom of the range, and it holds for flat-rate programmes at maintenance doses, where a dose-independent price beats a brand tier that rises to $449.

Before you conclude you have no coverage

Three checks are worth the twenty minutes, because any of them beats every self-pay figure above.

  1. Check your plan's formulary directly for Zepbound and Wegovy, and check whether the exclusion is for weight management specifically. Coverage for a diabetes indication is often separate.
  2. Ask about prior authorisation criteria. Many plans cover with documentation of BMI and comorbidities.
  3. Check manufacturer savings programmes, which are separate from the self-pay pricing above and have their own eligibility rules.

Where a commercial plan covers either brand, the cost can fall to roughly $25 a month. No self-pay route competes with that, and no compounded programme comes close.

Mean weight reduction by drug and dose, from the trials that produced each figureSeparate trials, different durations and populations
Tirzepatide 15 mg (SURMOUNT-1)21%Oral semaglutide 25 mg, adherent (17%Injectable semaglutide 2.4 mg (SUR14%Oral semaglutide 25 mg, treatment-14%Orforglipron 17.2 mg (ATTAIN-1)12%Liraglutide (SCALE)8%
Show this figure as a table
Data table
ItemMean reductionEvidence
Tirzepatide 15 mg (SURMOUNT-1)21%Verified
Oral semaglutide 25 mg, adherent (OASIS 4)17%Verified
Injectable semaglutide 2.4 mg (SURMOUNT-5)14%Verified
Oral semaglutide 25 mg, treatment-policy (OASIS 4)14%Verified
Orforglipron 17.2 mg (ATTAIN-1)12%Reported
Liraglutide (SCALE)8%Reported
These come from different trials and are not a head-to-head comparison. Durations differ (64 to 72 weeks) and estimands differ. Only SURMOUNT-5 compared two of these drugs directly.
Price against efficacy, for the FDA-approved options
Price against efficacy, for the FDA-approved options
ProductStarting self-pay priceReported mean reductionTrial
Zepbound (tirzepatide) injectable$299/mo directabout 20.9% at 15 mgSURMOUNT-1, 72 weeks
Wegovy pill (oral semaglutide 25 mg)$149/mo starting dose13.6–16.6% depending on estimandOASIS 4, 64 weeks
Wegovy injectable (semaglutide 2.4 mg)$349/mo maintenanceabout 13.7%SURMOUNT-5, 72 weeks
Foundayo (orforglipron)$149/mo starting doseabout 11–12.4% at 17.2 mgATTAIN-1, 72 weeks
Both $149 products are the least effective approved options in this table. That does not make them bad choices — it makes a price comparison that omits efficacy an incomplete one.
Where NexLife actually ranksNovember 2026

NexLife is our #1 pick, not the lowest price we track. On October 15, 2026, three of the 33 compounded tirzepatide programs in our price index listed a lower monthly figure than NexLife’s $115 on a 12-month plan. NexLife charges $129 a month month to month (read November 6, 2026).

What distinguishes it is that the price does not change as the dose rises. The FDA label states 2.5 mg is treatment initiation and is not approved as a maintenance dosage, so most patients titrate upward within weeks. Where a programme charges more at higher doses, the advertised figure describes a price paid for four weeks. NexLife (opens nexlife.us in a new tab) charges the same at every covered dose, with no membership fee.

Its prices are dated. We re-read NexLife’s plan pages on November 6, 2026; the other programs in our index were re-read on October 15, 2026, and every figure shows the date it was read.

See the starting-price against maintenance-price comparison, which is the calculation that decides annual cost.

Starting price, maintenance price, twelve-month totalTirzepatide programmes, ordered by advertised price
Starting price, maintenance price, twelve-month total
Provider and programmeAdvertised monthlyAt 10 mgTwelve monthsDose structure
NexLife (opens nexlife.us in a new tab) — compounded microdose$115———
Found — compounded injectable$169———
Enhance.MD — compounded microdose$169———
NexLife (opens nexlife.us in a new tab) — compounded injectable$115———
NexLife (opens nexlife.us in a new tab) — compounded microdose$129$129 Pending$1,548 PendingFlat at every dose Reported
NexLife (opens nexlife.us in a new tab) — compounded injectable$119$119 Verified$1,428 PendingFlat at every dose Verified
NexLife (opens nexlife.us in a new tab) — compounded injectable$125$125 Verified$1,500 PendingFlat at every dose Verified
Shed — compounded microdose$199———
NexLife (opens nexlife.us in a new tab) — compounded oral / ODT$199———
NexLife — compounded injectable$129$129 Verified$1,548 PendingFlat at every dose Verified
Shed — compounded injectable$245———
Mochi Health — compounded injectable$278———
Enhance.MD — compounded injectable$280———
Eden — compounded injectable$298———
Noom Med — compounded injectable$299———
LillyDirect — brand injectable, FDA-$299———

A dash means no figure held. How we grade evidence.

Blank cells in the maintenance and annual columns mean the provider does not publish an escalation ladder, so we cannot compute what treatment actually costs. That gap is the finding, not an omission on our part.
What twelve months actually costs, where we can compute it
Flat compounded, 12-month plan$1,380Flat compounded, month-to-month$1,548Approved oral held at a low dose$1,788Brand Zepbound following the label$5,188Medicare GLP-1 Bridge, if eligible$600Commercial coverage, typical copay$300
Show this figure as a table
Data table
ItemTwelve-month totalEvidence
Flat compounded, 12-month plan$1,380Verified
Flat compounded, month-to-month$1,548Reported
Approved oral held at a low dose$1,788Verified
Brand Zepbound following the label$5,188Verified
Medicare GLP-1 Bridge, if eligible$600Verified
Commercial coverage, typical copay$300Reported
A programme advertising less per month can cost more per year. Coverage beats every self-pay route by an order of magnitude.
The four routes, monthly
FDA-approved oral, starterOrforglipron $149Oral Wegovy $149FDA-approved injectable, direcZepbound 2.5mg $299Zepbound 7.5-15mg $449Compounded, lower bandTirzepatide $169Semaglutide $133Compounded, upper bandTirzepatide $399Semaglutide $299Brand resold near retailWegovy via platform $1,794Mounjaro via platform $2,048OrforglipronOral Wegovy
Show this figure as a table
Data table
ItemOrforglipronOral Wegovy
FDA-approved oral, starter$149$149
FDA-approved injectable, direct$299$449
Compounded, lower band$169$133
Compounded, upper band$399$299
Brand resold near retail$1,794$2,048
The bottom row is the same medicine the manufacturers sell direct for $349 and $299-$449 respectively.
What an all-in price is made of
Medication—Membership—Shipping—Dose surcharge—Consultation—Labs—Structure only. No widths are proportional to anything, because nothing is captured.
Show this figure as a table
Data table
ComponentAmount
Medicationnot captured
Membershipnot captured
Shippingnot captured
Dose surchargenot captured
Consultationnot captured
Labsnot captured
All-in totalnot captured
A provider that advertises only the first segment is quoting a price you cannot actually pay.
Where a headline price usually stops short
Where a headline price usually stops short
Cost componentInside the advertised figure?Charged anyway?
Medicationyesyes
Membership or program feeno—
Shippingno—
Higher-dose surchargeno—
Initial consultationno—
Required laboratory workno—
Cancellation or restocking termsno—

A dash means no figure held. How we grade evidence.

The right-hand column fills in per provider as capture proceeds. Until then it reads unverified, which is the honest state.
Approved product against compounded preparation
Approved product against compounded preparation
AttributeFDA-approved tirzepatide (Zepbound, Mounjaro)Compounded tirzepatide
Regulatory statusApproved finished drug productNot an FDA-approved product
Generic equivalentNo generic tirzepatide existsNot a generic and not therapeutically equivalent
Manufacturing standardManufactured under CGMPDepends on the compounder's registration class
Clinical trial evidenceStudied in the registration trialsTrials studied the approved product, not this preparation
LabellingFDA-approved labellingSupplied by the compounder
PresentationManufacturer's pens or vialsVaries; multi-dose vials add a measuring step
Price read on the seller’s own page——

A dash means no figure held. How we grade evidence.

No provider may describe a compounded preparation as FDA-approved or as generic Zepbound. Both statements are false, and both are common.
July 2026 records at a glanceas of 2026-07-24 (history)

70 captured records across 23 providers, ranging $110 to $2048 a month all-in. 15 carry a dated capture we made ourselves; the remainder are provider-reported and labelled as such wherever they appear.

Open the full price index · CSV · JSON

Take the data with youCC BY 4.0 with attribution

Pricing dataset, CSV · Pricing dataset, JSON

Suggested citation: Tirzepatide Ranked, Provider pricing dataset, S.J Partners LLC. Include the capture date shown in the file, not the download date.

Questions readers actually ask

How much does Zepbound cost without insurance?

Without insurance, Lilly's Zepbound self-pay savings card listed the KwikPen at $299 a month for 2.5 mg, $399 for 5 mg and $449 for 7.5 to 15 mg when each refill is bought within 45 days, according to Lilly's coverage page read October 15, 2026. Miss that window and the regular prices apply: $499 at 7.5 mg and $699 at 10 to 15 mg. The card covers up to 11 fills a calendar year, and its savings end December 31, 2026. Compounded tirzepatide costs less in our index, but it is not FDA-approved and is not the same product as Zepbound.

What is the cheapest way to get tirzepatide without insurance?

For the approved drug, LillyDirect at $299 for the starter vial. For the cheapest approved GLP-1 of any kind, orforglipron or oral Wegovy tablets at $149. Compounded programmes start lower but are not FDA-approved.

Should I buy brand drugs through a telehealth platform?

Price it at the manufacturer first. Some platforms resell brand drugs at four to twelve times the manufacturer's own direct self-pay price.

Cite this pageCC BY 4.0

Tirzepatide Ranked. “Tirzepatide Cost Without Insurance.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/tirzepatide-cost-without-insurance/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.

Comparing 0 of 4